// App-Quantinova.ai

: Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status

Researchers

Presenter

  • Olivier Decaux

Principal Investigators

  • Radhia Lafore

  • Daniel Iaquinta

  • Christina Tekle

  • Xavier Leleu

Medical Centers

  • Service d'hématologie clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France

  • Centre Hospitalo-Universitaire (CHU) La Mileterie, INSERM CIC , Poitiers, France

  • Université de Rennes , INSERM, Établissement Français du Sang de Bretagne, Unité Mixte de Recherche (UMR)_S, Rennes, France

Locations

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Isatuximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved